Dopl Technologies, a Bothell, Washington-based medical technology company developing a robotic ultrasound platform, today announced it has closed a $6.3 million seed round led by SpringTide Ventures. The round raised Dopl's total funding to more than $8 million. Its investor base includes more than a dozen firms, comprising strategic, institutional, and community-focused investors from across the United States..

总部位于华盛顿州博瑟尔的医疗科技公司 Dopl Technologies 致力于开发机器人超声平台，今日宣布已完成由 SpringTide Ventures 领投的 630 万美元种子轮融资。此轮融资使 Dopl 的总融资额超过 800 万美元。其投资者群体包括来自全美各地的十余家机构，涵盖战略投资者、机构投资者以及关注社区发展的投资者。

With the new funding, Dopl will pursue FDA clearance for its product ecosystem, which includes Traverse™, a remote robotic ultrasound system; Dopl Connect™, a secure connectivity and data platform; and SonoFlex™, a distributed clinical workforce and workflow management solution. The distributed care platform will enable sonographers to remotely perform diagnostic ultrasound exams for patients on demand across multiple sites, often in rural communities where access to specialized care has been historically limited..

凭借新获得的资金，Dopl 将为其产品生态系统寻求美国食品药品监督管理局（FDA）的批准。该生态系统包括：Traverse™，一种远程机器人超声系统；Dopl Connect™，一个安全的连接与数据平台；以及 SonoFlex™，一种分布式临床人力与工作流管理解决方案。该分布式护理平台将使超声医师能够按需为多个地点的患者远程执行诊断性超声检查，这些地点通常位于历史上专业医疗资源获取受限的农村地区。

The funding will support product verification and validation, FDA submission and clearance activities, clinical evaluation, and initial market release. Dopl's platform is hardware-agnostic, integrating off-the-shelf robots, ultrasound systems, haptic controllers, and cameras to enable rapid deployment across existing hospital infrastructure..

这笔资金将支持产品验证与确认、FDA 申报与审批、临床评估以及初步市场发布。Dopl 的平台具有硬件无关性，能够集成现成的机器人、超声系统、力反馈控制器和摄像头，从而在现有医院基础设施中实现快速部署。

Dopl's growing team brings extensive expertise across robotics, AI, medical devices, and clinical operations. Founded by a former NVIDIA medical AI engineer alongside practicing cardiologists and radiologists, the broader team offers experience from Butterfly Network, Philips, Microsoft, and Amazon..

Dopl 不断壮大的团队在机器人技术、人工智能、医疗器械和临床运营方面拥有广泛的专业知识。公司由一位前 NVIDIA 医疗 AI 工程师与多位执业心脏病学家和放射科医生共同创立，其更广泛的团队成员则来自 Butterfly Network、飞利浦、微软和亚马逊等企业，拥有丰富的行业经验。

“Our outstanding team is energized and now capitalized to move quickly through the regulatory process to deliver reliable, remote robotic ultrasound to patients who today must often travel hours to receive essential care,” said Ryan James, PhD, CEO and Co-founder of Dopl Technologies. “This is a critical step toward providing specialty care, anywhere, through telerobotic and autonomous care delivery, bridging the healthcare divide that affects tens of millions of people in the United States alone.”.

Dopl Technologies 首席执行官兼联合创始人瑞安·詹姆斯博士表示：“我们出色的团队充满活力，且资金充足，能够快速推进监管审批流程，为那些如今往往需要长途跋涉数小时才能获得基本护理的患者提供可靠的远程机器人超声检查服务。这是通过远程机器人和自主护理交付方式，在任何地方提供专科护理的关键一步，有助于弥合仅在美国就影响数千万人的医疗鸿沟。”

Dopl launched its current ultrasound service, CareBridge™, to temporarily address patient needs while pursuing FDA clearance, build partner relationships, and provide Dopl with direct insights from patients and providers. CareBridge delivers select hospitals with immediate, in-person coverage from traveling sonographers, ensuring uninterrupted, end-to-end diagnostic ultrasound care.

Dopl 推出了其当前的超声服务 CareBridge™，以在寻求美国食品药品监督管理局（FDA）批准期间临时满足患者需求，建立合作伙伴关系，并使 Dopl 能够直接从患者和医疗服务提供者处获得洞察。CareBridge 为选定医院提供由流动超声技师进行的即时现场覆盖，确保不间断的端到端诊断超声护理。

Patients in communities where Dopl operates see up to a 90% reduction in wait times. These select hospital systems are planned to be the first to pilot a transition of their imaging services to Dopl’s telerobotic ecosystem upon FDA clearance..

在Dopl运营的社区中，患者的等待时间最多可减少90%。这些精选的医院系统计划在获得美国食品药品监督管理局（FDA）批准后，率先试点将其影像服务过渡到Dopl的远程机器人生态系统。

“We're excited to support Dopl Technologies and its unique, category-defining approach as a physical AI company. Dopl is primed to deliver a cost-efficient, revenue-generating model for health systems, enabling skilled sonographers to work from home, allowing more patients to receive care when and where they need it most,” said Austin Walters, Co-founder and Managing Partner of SpringTide Ventures.

“我们很高兴支持 Dopl Technologies 及其作为一家实体人工智能公司所采用的独特、开创性方法。Dopl 已准备好为医疗系统提供一种成本效益高且能创造收入的模式，使熟练的超声技师能够居家工作，从而让更多患者在最需要的时候和地点获得护理，”SpringTide Ventures 的联合创始人兼管理合伙人 Austin Walters 表示。

“Dopl's combination of proven clinical traction, innovative, integrated technologies, and an experienced team positions it to lead the coming wave of robotic care delivery, and we believe it will democratize how and where imaging is available.”.

“Dopl 凭借经临床验证的强劲势头、创新的集成技术以及经验丰富的团队，有望引领即将到来的机器人化护理服务浪潮；我们相信，它将使影像检查的可及性在方式和地点上更加普及。”

SpringTide Ventures is joined by WRF Capital, Tacoma Venture Fund (pre-seed lead), HeartX, Transform Health Ventures, Precursor Ventures, and additional early-stage institutional investors.

SpringTide Ventures 与 WRF Capital、Tacoma Venture Fund（前种子轮领投方）、HeartX、Transform Health Ventures、Precursor Ventures 以及其他早期机构投资者共同参与。

Follow Dopl Technologies on LinkedIn and sign up to receive the latest news and information.

在 LinkedIn 上关注 Dopl Technologies，并注册以获取最新新闻和信息。

About Dopl Technologies

关于 Dopl Technologies

Dopl Technologies, founded in 2022, leverages robotics, AI, and remote clinical expertise to bring high-quality diagnostic ultrasound to patients who need it most — regardless of where they live. Headquartered in Bothell, Washington, Dopl's current service offering, CareBridge, connects credentialed remote sonographers to patients at the point of care, closing an access gap that affects more than 50 million people in the United States alone.

Dopl Technologies 成立于 2022 年，利用机器人技术、人工智能和远程临床专业知识，为最需要高质量诊断超声服务的患者提供服务，无论他们居住在哪里。公司总部位于华盛顿州博塞尔，其当前的服务产品 CareBridge 将具备资质的远程超声医师与护理点的患者连接起来，弥合了仅在美国就影响超过 5000 万人的医疗可及性差距。

The company estimates a $40 billion annual reimbursement opportunity for U.S. hospitals as telerobotic imaging scales nationally..

随着远程机器人成像技术在全国范围内的推广，该公司估计美国医院每年的报销机会将达到400亿美元。

Dopl has completed FDA pre-submission engagement, established a 510(k) regulatory pathway, and developed patented technology. Dopl is trusted by a number of critical access hospitals across Washington State.

Dopl 已完成与美国食品药品监督管理局（FDA）的预提交沟通，确立了 510(k) 监管路径，并开发了专利技术。Dopl 受到华盛顿州多家关键接入医院的信赖。

Contacts

联系人

Media Contact:

媒体联系人：

Eric Schudiske

埃里克·舒迪斯克

media@dopltechnologies.com

media@dopltechnologies.com

Source: businesswire.com

来源：businesswire.com